Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07571538 · ClinicalTrials.gov registry record · NA
VisionApp - Ghosting
A NA study, sponsored by Indiana University.
- Recruiting
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT07571538: Recruiting NA study, sponsored by Indiana University.
NCT07571538 is a NA study that is actively recruiting participants, run by Indiana University. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07571538, a NA study, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
Recent Android mobile device technology is available which allows user-measured refractive error and reading add power. This technology could be quite useful to the clinical and research community. The current study aims to evaluate the accuracy, repeatability, and reproducibility of one such technology by VisionApp, specifically with regard to ghosting vision. VisionApp is an app which runs on a smartphone or other device which uses the distance between the user's face and the phone to determine refractive error, while the user looks at different targets (lines, letters, words, etc).
Primary Outcome
Ghosting quantification (e.g. how "doubled" the image looks) will be compared against expected template images and those predicted. Subjects will provide a quality rating of ghosting on a scale between 0 - 100, with lower scores indicating more ghosting of the image and 100 representing an optically perfect image. The VisionApp will also model ghosting measurements for direction, separation, blur and strength into a predictive quality rating, which will be compared to the subject's subjective e
Interventions
- DEVICE Proclear 1 Day Contact Lens
- DEVICE MyDay Contact Lens
- DEVICE NaturalVue Contact Lens
- DEVICE MiSight 1 Day Contact Lens
- DEVICE Investigational Contact Lens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-10-10 |
| Est. Completion | 2026-08-01 |
| Phase | NA |
What NCT07571538 shows while recruiting
NCT07571538 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 5 interventions - of which Proclear 1 Day Contact Lens is the first listed.
NCT07571538 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07571538 about?
NCT07571538 is a clinical study titled "VisionApp - Ghosting". Recent Android mobile device technology is available which allows user-measured refractive error and reading add power. This technology could be quite useful to the clinical and research community. The current study aims to evaluate the accuracy, repeatability, and reproducibility of one such techno...
What is the current status of trial NCT07571538?
This trial is currently recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2025-10-10. Estimated completion is 2026-08-01.
What interventions are being tested in trial NCT07571538?
The interventions under investigation include: Proclear 1 Day Contact Lens (DEVICE), MyDay Contact Lens (DEVICE), NaturalVue Contact Lens (DEVICE), MiSight 1 Day Contact Lens (DEVICE), Investigational Contact Lens (DEVICE).
Who is sponsoring clinical trial NCT07571538?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07571538's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI